Merck KGaA Invests in Biopharmaceuticals Fill-Finish Site
Merck KGaA fill-finish expansion in Italy will be completed in 2017.
Merck KGaA plans to invest €50 million (68 million USD) in its Italian production site in Bari to respond to the rising demand for biopharmaceuticals, the company announced in a press release. The expansion is part of the company's "Fit for 2018" transformation and growth program.
Within the biopharmaceuticals division, the Bari site is part of Merck's fill & finish operations, along with facilities in Darmstadt and Aubonne (Switzerland). The drugs produced within this global network, particularly those used to treat infertility, are experiencing long-term growing demand. The new production facility in Bari will be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials, and ampoules.
Source: Merck KGaA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
